doctors refuse to approve the new treatment
Botulax

Content prepared by Direct Doctor Supply’s Editorial team.


Last Updated On September 16, 2026

Is Botulax FDA-Approved?

Jul 21, 2025

In a 2021 review, it was noted that at least six formulations of botulinum toxin have received FDA approval for various neurological and cosmetic uses. Each product has undergone rigorous evaluation to ensure it meets the FDA’s high standards for safety, efficacy, and pharmacological properties. This growing list reflects the rising demand for botulinum toxin treatments and the FDA’s evolving approach to biologics.

One such product is Botulax, a botulinum toxin type A developed by South Korean manufacturer Hugel. Rebranded as Letybo for the U.S. market, Botulax received FDA approval in February 2024 for treating moderate to severe glabellar lines. This approval followed extensive clinical trials and regulatory reviews, marking Botulax as part of an exclusive group of globally recognized neurotoxins.

In this article, we’ll take a closer look at Botulax’s FDA approval journey, clarify its regulatory status, and explore what this means for practitioners and consumers seeking safe, effective alternatives for aesthetic treatments.

Key Takeaways

  • Botulax is a botulinum toxin type A product from Hugel in South Korea. While it has approval in several international markets, including South Korea and the European Union, it does not have FDA approval in the United States.
  • Botulax’s use in the U.S. violates federal regulations, which may lead to legal risks such as customs seizure, malpractice lawsuits, and sanctions for healthcare providers who use or import it.
  • The lack of FDA approval means that Botulax cannot be legally marketed or used in clinical settings in the U.S., making it a high-risk option for practitioners and patients looking for safe and compliant treatments.
  • Despite its regulatory limitations, Botulax is gaining popularity in international markets due to its affordability and comparable performance to FDA-approved botulinum toxin products, with many practitioners reporting positive patient outcomes.
  • Clinics in the U.S. should use FDA-approved injectables to ensure patient safety and comply with legal standards, as the risks associated with using Botulax are significant.
Consult our sales team

If you’re interested in this product.

Book a Meeting


About: Trusted by over 2,000+ global clients since 2014, Direct Doctor Supply has become a leading supplier of cosmetic, skincare, and orthopedic products for medical and aesthetic professionals. Direct Doctor Supply offers a wide range of authentic brand-name products at competitive wholesale prices, sourced from around the world.

Botulax FDA Status & U.S. Regulatory Context

The regulatory status of Botulax in the United States requires an important distinction. HUGEL’s botulinum toxin type A formulation is FDA-approved in the U.S. under the trade name LETYBO (letibotulinumtoxinA-wlbg), which received approval on February 29, 2024 for the temporary improvement of moderate-to-severe glabellar lines in adults. However, Botulax itself is not the FDA-approved U.S. trade name, and regulatory authorization can differ by country, presentation, and labeling [1].

Clinical Study: LetibotulinumtoxinA for Glabellar Lines

A randomized, double-blind, placebo-controlled Phase III trial evaluated HUGEL’s letibotulinumtoxinA in 355 adults with moderate-to-severe glabellar lines. At Week 4, the composite responder rate was 64.7% with active treatment compared with 0% with placebo, and the median onset of effect was approximately three days. The treatment was also reported to be well tolerated. These clinical data formed part of the broader evidence supporting letibotulinumtoxinA as an aesthetic botulinum toxin treatment [3].

For professionals researching where to buy Botulax online, the key consideration is the regulatory status of the exact product in the country where it will be supplied and administered. In the U.S., practitioners should use the FDA-approved LETYBO presentation rather than assume that an internationally marketed Botulax product carries the same U.S. authorization. FDA labeling also states that LETYBO potency units are product-specific and cannot be directly converted to units of other botulinum toxin preparations.

Botulax International Approvals: MFDS, CE, Other Markets

While Botulax does not have FDA approval, it has regulatory clearance in several international markets. These approvals vary in terms of safety, efficacy, and distribution standards, but they do not imply that the product is legally accepted for use in the U.S [2].

reviewing the medicine's record

Here’s a breakdown of Botulax’s regulatory status in different regions:

  • South Korea (MFDS): Approved for both aesthetic and therapeutic use based on controlled studies that confirmed safety and effectiveness.
  • European Union (CE Certification): Compliant with EU health, safety, and environmental standards, allowing distribution within Europe but not for use in the U.S.
  • Other Markets: Available in select countries across Southeast Asia, Latin America, and the Middle East, where it adheres to varying local regulations.

Each of these approvals highlights Botulax’s growing global presence but underscores the distinction between its use abroad and the lack of approval in the U.S.. Understanding these differences is critical for clinics, distributors, and patients who are navigating the complexities of international treatments.

Using or offering Botulax in the U.S. is not only legally risky, but it also carries professional and ethical concerns. Since the product is not FDA-approved, any use for cosmetic or medical purposes is considered off-market and unauthorized. Here are the key legal and professional risks:

  • Importation Risk: Clinics or individuals importing Botulax may face customs seizure or FDA investigation, which can cause significant disruptions to business operations.
  • Liability Exposure: Using an unapproved injectable exposes practitioners to potential malpractice lawsuits and disciplinary action from licensing boards.
  • Insurance Issues: Malpractice insurers may deny coverage for claims related to unapproved products like Botulax, leaving practitioners vulnerable to out-of-pocket expenses.
  • Professional Licensing: State medical boards may impose sanctions or even suspend licenses for using unauthorized products.
  • Patient Safety: Without FDA oversight, there’s no assurance that Botulax meets the same standards for product quality, sterility, or manufacturing consistency as FDA-approved injectables.

For healthcare professionals in the U.S., it is strongly advised to use FDA-approved products for injectables to remain compliant with legal standards and ensure patient safety.

In markets where it is legally distributed, Botulax is gaining popularity due to its affordability and comparable performance to FDA-approved botulinum toxins. Many international practitioners report positive patient outcomes with Botulax, especially for mild to moderate cases.

vials in the machine

However, its lack of FDA approval remains a significant concern for U.S. practitioners who are cautious about sourcing and safety protocols. Despite the positive feedback abroad, Botulax’s unregulated status in the U.S. prevents many American professionals from using it in clinical settings.

Here’s a breakdown of global practitioner perspectives:

  • Affordability: Practitioners see Botulax as a cost-effective alternative for clinics managing tight budgets, offering comparable results to higher-priced brands.
  • Consistency: Practitioners report reliable results as long as they obtain and use Botulax from certified distributors.
  • Patient Satisfaction: The effects of Botulax are comparable to more expensive U.S. brands, making it an attractive option for patients looking for budget-friendly treatments.
  • Regulatory Caution: Many U.S. clinics avoid Botulax due to its lack of FDA approval and the associated compliance concerns.

Despite these challenges, Botulax continues to expand in international markets, with guides like the Botulax instructions helping standardize application techniques. However, U.S. professionals must exercise caution when considering this treatment option.

Conclusion

Botulax has made significant strides internationally, gaining approval in markets like South Korea, the European Union, and other regions. However, it remains unapproved by the FDA for use in the U.S., making its importation, sale, or administration a violation of U.S. regulations.

While it shows promise abroad, Botulax has not yet met the rigorous safety and efficacy standards required for FDA approval in the U.S. Until it does, U.S. practitioners are advised to avoid using Botulax for cosmetic or medical treatments. They should stick to FDA-approved alternatives to ensure patient safety and legal compliance.

FAQs

1. Is Botulax approved by the FDA?

No. Botulax does not have FDA approval. Because of this, healthcare professionals in the United States cannot legally market or use it for aesthetic treatments.

2. Can I buy Botulax in the U.S. legally?

No. Importing or purchasing Botulax for personal or professional use in the U.S. is not allowed under FDA regulations.

3. What countries have approved Botulax?

Botulax has regulatory approval in South Korea. It also has CE certification for use in parts of Europe and other select regions.

4. Is Botulax safe to use?

International studies show Botulax is generally safe when administered properly, but the FDA has not confirmed safety in the U.S..

5. Why is FDA approval essential?

FDA approval ensures that a product meets strict standards for safety, efficacy, and manufacturing quality before clinicians in the U.S. can use it.

6. Are there FDA-approved alternatives to Botulax?

Yes. FDA-approved alternatives include Botox, Dysport, Xeomin, and Jeuveau, all of which are available through licensed U.S. providers.

7. What should I ask before getting any injectable?

Ask about the product’s FDA approval status, where it’s sourced, and if the provider is licensed to perform the treatment.

Need help, additional info, or customized deals?

Talk with our sales representative.

Book a Meeting

Citations

[1] Choudhury, Sujata, M. R. Baker, S. Chatterjee, and H. Kumar. “Botulinum Toxin: An Update on Pharmacology and Newer Products in Development.” Toxins, vol. 13, no. 1, 2021, article 58. https://doi.org/10.3390/toxins13010058.

[2] Frevert, J., K. Y. Ahn, M. Y. Park, and O. Sunga. “Comparison of Xeomin® to Botulinum Neurotoxin Type A Formulations in Asia.” Toxicon, vol. 156, 2018, p. S37. https://doi.org/10.1016/j.toxicon.2018.11.090.

[3] U.S. Food and Drug Administration. “Drug Trials Snapshots: LETYBO.” U.S. Food and Drug Administration, https://www.fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshots-letybo.

Sourcing and accuracy for this article follow our Editorial policy: claims are cross-checked against clinical literature, regulatory filings, and manufacturer specifications before anything is published